Clinical Trial Update: Study of Alimta in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Who Have Had Prior Platinum Based Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pemetrexed (Alimta) in patients with recurrent or metastatic nasopharyngeal carcinoma after platinum-based chemotherapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Alimta (pemetrexed)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Nasopharyngeal Neoplasms | Phase 2 | Status: COMPLETED